×
About 31,738 results

ALLMedicine™ Multiple Myeloma Center

Research & Reviews  9,893 results

Melflufen for multiple myeloma: a promise unfulfilled?
https://doi.org/10.1016/S2352-3026(22)00002-3
The Lancet. Haematology; Kapoor P, Gonsalves WI

Jan 16th, 2022 - Melflufen for multiple myeloma: a promise unfulfilled?|2022|Kapoor P,Gonsalves WI,|

Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refract...
https://doi.org/10.1016/S2352-3026(21)00381-1
The Lancet. Haematology; Schjesvold FH, Dimopoulos MA et. al.

Jan 16th, 2022 - Melphalan flufenamide (melflufen), an alkylating peptide-drug conjugate, plus dexamethasone showed clinical activity and manageable safety in the phase 2 HORIZON study. We aimed to determine whether melflufen plus dexamethasone would provide a pro...

Impact of Frailty on Hospital Outcomes Among Patients with Lymphoid Malignancies Receiv...
https://doi.org/10.1016/j.clml.2021.12.017
Clinical Lymphoma, Myeloma & Leukemia; Rubens M, Cristian A et. al.

Jan 15th, 2022 - Frailty could affect outcomes of autologous hematopoietic stem cell transplantation (aHSCT). This study sought to examine the effects of frailty on hospital outcomes among patients with non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), and multip...

Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory m...
https://doi.org/10.1038/s41375-021-01492-y
Leukemia Waldschmidt JM, Yee AJ et. al.

Jan 15th, 2022 - Interrogation of cell-free DNA (cfDNA) represents an emerging approach to non-invasively estimate disease burden in multiple myeloma (MM). Here, we examined low-pass whole genome sequencing (LPWGS) of cfDNA for its predictive value in relapsed/ re...

see more →

Guidelines  34 results

Management of adults and children receiving CAR T-cell therapy: 2021 best practice reco...
https://doi.org/10.1016/j.annonc.2021.12.003
Annals of Oncology : Official Journal of the European Soc... Hayden PJ, Roddie C et. al.

Dec 20th, 2021 - Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lympho...

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and fo...
https://doi.org/10.1016/j.annonc.2020.11.014
Annals of Oncology : Official Journal of the European Soc... Dimopoulos MA, Moreau P et. al.

Feb 8th, 2021 - Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.|2021|Dimopoulos MA,Moreau P,Terpos E,Mateos MV,Zweegman S,|diagnosis,epidemiology,therapy,

Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2020.0057
Journal of the National Comprehensive Cancer Network : JN... Kumar SK, Callander NS et. al.

Dec 8th, 2020 - Multiple myeloma is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. This manuscript discusses the management of patients with solitary plasmacytoma, smoldering multiple myeloma, ...

KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological mali...
https://doi.org/10.1016/j.kint.2020.07.012
Kidney International; Małyszko J, Bamias A et. al.

Dec 6th, 2020 - The bidirectional relationship between cancer and chronic kidney disease (CKD) is complex. Patients with cancer, particularly those with hematological malignancies such as multiple myeloma and lymphoma, are at increased risk of developing acute ki...

Mobilization and Exercise Intervention for Patients With Multiple Myeloma: Clinical Pra...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781094
Physical Therapy; Jeevanantham D, Rajendran V et. al.

Sep 26th, 2020 - Individuals with multiple myeloma (MM) often have reduced functional performance due to the cancer itself or as a direct side effect of cancer treatments. Physical therapy is a part of cancer rehabilitation; however, no guidelines are available to...

see more →

Drugs  143 results see all →

Clinicaltrials.gov  815 results

A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT03170882

Jan 14th, 2022 - The drug being tested in this study is called Ixazomib. Ixazomib is being tested to treat people who have relapsed and/or refractory multiple myeloma (RRMM). This study will compare the efficacy and safety in participants who take ixazomib and dex...

MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT05020236

Jan 14th, 2022 - The purpose of this study is to evaluate whether the BCMA-CD3 bispecific antibody elranatamab, alone and/or in combination with the anti-CD38 monoclonal antibody, daratumumab, can provide more benefit to people with multiple myeloma compared to a ...

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
https://clinicaltrials.gov/ct2/show/NCT02465060

Jan 14th, 2022 - PRIMARY OBJECTIVE: I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma. SECONDARY OBJECTIVES: I. To evaluate the proportion of pa...

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT04933539

Jan 14th, 2022 - Background: Smoldering multiple myeloma (SMM) is a precursor condition to MM defined by the clinical parameters of M-protein >=3.0 g/dL or bone marrow plasma cells >=10%, and absence of end organ disease. Patients with high-risk SMM have a risk of...

see more →

News  1,786 results

Selecting the Optimal Treatment Approach for Difficult-to-Treat, Relapsed/Refractory Myeloma
https://www.onclive.com/view/selecting-the-optimal-treatment-approach-for-difficult-to-treat-relapsed-refractory-myeloma

Jan 14th, 2022 - Certain patient and disease characteristics must be considered to select the optimal treatment approach for difficult-to-treat patients with relapsed or refractory multiple myeloma, according to Alessandra Larocca, MD, PhD, who added that the intr...

Fast Five Quiz: Are You Prepared to Confront Multiple Myeloma?
https://www.medscape.com/viewarticle/842817

Jan 14th, 2022 - Multiple myeloma is a debilitating malignancy that is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. Because the antibody-forming cells (ie, plasma cells) are malignant, th...

Fast Five Quiz: Multiple Myeloma Management
https://reference.medscape.com/viewarticle/949631

Jan 11th, 2022 - Multiple myeloma is a hematologic cancer in which monoclonal plasma cells proliferate in the bone marrow, destroying bone and displacing other hematopoietic cell lines. Its presentation can range from asymptomatic to severely symptomatic, with com...

Fast Five Quiz: Multiple Myeloma Management
https://www.medscape.com/viewarticle/949631

Jan 11th, 2022 - Multiple myeloma is a hematologic cancer in which monoclonal plasma cells proliferate in the bone marrow, destroying bone and displacing other hematopoietic cell lines. Its presentation can range from asymptomatic to severely symptomatic, with com...

Fast Five Quiz: Relapsed/Refractory Multiple Myeloma
https://www.medscape.com/viewarticle/962961

Jan 11th, 2022 - Multiple myeloma is a plasma cell cancer characterized by proliferation of monoclonal plasma cells in bone marrow, leading to an overabundance of monoclonal paraprotein (M protein), destruction of bone, and displacement of other hematopoietic cell...

see more →

Patient Education  24 results see all →